Moreover, it has been demonstrated in both type 1 and type 2 diabetes animal models that treatment with DPP-IV inhibitors preserves islet function and increases pancreatic insulin content, through an increase in proliferation, neogenesis, and apoptosis resistance of β-cells [29]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.